Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

515 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Correction: Impact of a comprehensive geriatric assessment to manage elderly patients with locally advanced non-small-cell lung cancers: a multicenter prospective study.
Rondan MA, Sánchez-Hernández A, Estellés DL, Sánchez JG, Aparisi FAA, López JS, Benajes RT, Sarrió RG. Rondan MA, et al. Among authors: sanchez hernandez a. Clin Transl Oncol. 2024 Nov 16. doi: 10.1007/s12094-024-03766-0. Online ahead of print. Clin Transl Oncol. 2024. PMID: 39549211 No abstract available.
A real‑world study of clinical characteristics, treatment sequence and outcomes of patients with non-small cell lung cancer and EGFR exon 20 insertion mutations.
Suay G, Martín-Martorell P, Aparisi F, Arnal M, Guirado M, Azkárate A, Garde-Noguera J, Cumplido-Burón JD, Insa A, González-Muñoz JF, Palanca S, Díaz M, Sánchez-Hernández A, Juan-Vidal Ó. Suay G, et al. Among authors: sanchez hernandez a. Clin Transl Oncol. 2024 Nov 5. doi: 10.1007/s12094-024-03776-y. Online ahead of print. Clin Transl Oncol. 2024. PMID: 39499485
Quantification of circulating endothelial cells as a predictor of response to chemotherapy with platinum and pemetrexed in patients with advanced non-squamous non-small cell lung carcinoma.
Sánchez Hernández A, José Juan O, Vidal Martínez J, Blanco R, Maciá S, Esquerdo Galiana G, Aparisi Aparisi F, Garde Noguera J, Catot S, Losa Gaspá F, García-Piñon F. Sánchez Hernández A, et al. Clin Transl Oncol. 2015 Apr;17(4):281-8. doi: 10.1007/s12094-014-1223-5. Epub 2014 Sep 19. Clin Transl Oncol. 2015. PMID: 25236392
Advanced non-squamous NSCLC with no actionable oncogenic driver in Spain: a cross-sectional descriptive analysis of data from the Thoracic Tumor Registry.
Carcereny E, Rodriguez-Abreu D, Lopez R, Franco F, Guirado M, Massutí B, Cobo M, Blasco A, Suay G, Del Barco E, Ortega AL, Sala MA, Cordeiro P, Bernabé R, González Larriba JL, Bosch-Barrera J, Calzas J, Casal J, Padilla A, Sánchez-Hernandez A, Provencio M. Carcereny E, et al. Clin Transl Oncol. 2024 Dec;26(12):3218-3225. doi: 10.1007/s12094-024-03511-7. Epub 2024 Jun 11. Clin Transl Oncol. 2024. PMID: 38862862
Intercalated Dosing Schedule of Erlotinib and Docetaxel as a Therapeutic Strategy to Avoid Antagonism and Optimize Its Benefits in Advanced Non-Small-Cell Lung Cancer. A Randomized Phase II Clinical Trial.
Juan Ó, Aparisi F, Sánchez-Hernández A, Muñoz-Langa J, Esquerdo G, García-Sánchez J, López A, Garde J, Giner V. Juan Ó, et al. Clin Lung Cancer. 2015 May;16(3):193-9. doi: 10.1016/j.cllc.2014.11.006. Epub 2014 Nov 23. Clin Lung Cancer. 2015. PMID: 25547902 Clinical Trial.
COAST: An Open-Label, Phase II, Multidrug Platform Study of Durvalumab Alone or in Combination With Oleclumab or Monalizumab in Patients With Unresectable, Stage III Non-Small-Cell Lung Cancer.
Herbst RS, Majem M, Barlesi F, Carcereny E, Chu Q, Monnet I, Sanchez-Hernandez A, Dakhil S, Camidge DR, Winzer L, Soo-Hoo Y, Cooper ZA, Kumar R, Bothos J, Aggarwal C, Martinez-Marti A. Herbst RS, et al. J Clin Oncol. 2022 Oct 10;40(29):3383-3393. doi: 10.1200/JCO.22.00227. Epub 2022 Apr 22. J Clin Oncol. 2022. PMID: 35452273 Clinical Trial.
515 results